During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants about quadruplet vs triplet regimens and the goals of deep responses in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.
In an in-person Community Case Forum event in partnership with the North Carolina Oncology Association and South Carolina Oncology Society, Daniel Carrizosa, MD, MS, discussed the use of the immunotherapies durvalumab and atezolizumab in patients with small cell lung cancer.
During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed how the burgeoning use of chimeric antigen receptor T-cell therapy presents a paradigm shift in treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
In separate live virtual events, James K. McCloskey II, MD, and Bart L. Scott, MD, polled participants on disease symptoms and bridging therapy options for a patient with primary myelofibrosis (PMF).
During a Case-Based Roundtable® event, Timothy J. Pluard, MD, discussed the use of sacituzumab govitecan advanced breast cancer as well as dosing considerations in the first article of a 2-part series.
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, asked participants their perspectives on the use of targeted agents for patients with ALK+ non–small cell lung cancer in the second article of a 2-part series.
During a Case-Based Roundtable® event, Sumanta K. Pal, MD, moderated a discussion on quality of life data and experiences with dose discontinuation of frontline combination therapy for patients with renal cell carcinoma.
During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.
During a Case-Based Roundtable® event, Alvaro Jose Alencar, MD, moderated a peer discussion on treatment options for a patient with diffuse large B-cell lymphoma whose disease relapsed eight months after completion of standard R-CHOP.
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
During a Case-Based Roundtable® event, Jubilee Brown, MD, discussed the efficacy and safety data from the KEYNOTE-775/Study 309 trial of lenvatinib plus pembrolizumab in patients with mismatch repair proficient advanced endometrial cancer.
During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
During a Case-Based Roundtable® event, Michael B. Atkins, MD, discussed the choice of therapy for a 78-year-old patient with metastatic melanoma with participants.
During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
During a Case-Based Roundtable® event, Natalia Neparidze, MD, discussed the studies that led to accelerated approval of the bispecific T-cell engagers teclistamab and elranatamab in patients with relapsed/refractory multiple myeloma.
During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.
During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the deep response with pacritinib and its adverse event profile for patients with myelofibrosis in the second article of a 2-part series.
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the benefits of using CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.